WeForNews | Latest News, Breaking News, News Updates In take of green tea may hamper fertility: Study | WeForNews | Latest News, Blogs
Connect with us

Health

In take of green tea may hamper fertility: Study

Published

on

The cup packed with anti-oxidants and other health benefits may adversely affect your fertility and development in case of frequent use, warn researchers.

In experiments over fruit flies, the team from University of California-Irvine discovered that excessive consumption adversely affected development and reproduction in fruit fly populations.

According to them, one should avoid high dose of green tea or any natural product as nutraceuticals such as green tea, while growing in popularity, are largely unregulated.

“While green tea could have health benefits at low doses, our study and others have shown that at high doses, it may have adverse effects,” said Mahtab Jafari, associate professor of pharmaceutical sciences.

“Further work is needed to make any definite recommendations but we suggest that green tea should be consumed in moderation,” she added.

For the study, Jafari and colleagues investigated the effects of green tea toxicity on the development and reproduction in fruit fly Drosophila melanogaster.

Embryos and larvae were subjected to various doses of green tea polyphenols.

Larvae exposed to 10 milligrams of green tea were slower to develop, were born smaller and exhibited a dramatic decline in the number of emerged offspring.

Ten milligrams of green tea made the flies more susceptible to starvation and heat stress but protected them against dehydration.

Female offspring showed decreased reproductive output and a 17 percent reduction in lifespan while males were unaffected, the study found.

Ten milligrams of green tea caused morphological abnormalities in reproductive organs such as testicular and ovarian atrophy.

Jafari believes that high doses of green tea may cause “too much” apoptosis or cell death.

Derived from the plant Camellia sinensis, green tea is popular worldwide for its purported brain and heart health and anti-cancer properties.

Jafari noted that in other tests with mice and dogs, green tea compounds in large amounts dramatically reduced body weight and, in mice, negatively affected embryo development.

“We are planning to measure total consumption and identify and quantify the metabolites of natural products in flies,” Jafari pointed out, adding that these experiments will enable us to have a better knowing of toxic doses in humans.

wefornews bureau

Health

Expert panel recommends Phase 1 trial of nasal Covid-19 vaccine

According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19.

Published

on

By

nasal spray vaccine covid

New Delhi, Jan 20: The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday recommended Bharat Biotech’s intranasal vaccine for coronavirus for phase 1 clinical trials. The final call will now be taken by the Drugs Controller General of India.

Days after getting the Drugs Controller General of India’s nod for restricted emergency use of India’s first indigenously-made coronavirus vaccine, Bharat Biotech had applied to the drug regulator for permission to start the clinical trials of their nasal coronavirus vaccine.

The nasal vaccine is different from the intramuscular vaccine which recently got approval, as it is non-invasive, needle-free, doesn’t require trained healthcare workers, eliminates needle-associated risks, suits children and adults and has scalable manufacturing.

Earlier on Tuesday, Dr VK Paul, Member, NITI (National Institution for Transforming India) Aayog had said, “A nasal vaccine candidate has been identified. It has come for consideration for phase 1 and phase 2 trials. If it works then it could be a game-changer.”

“Phase 1 has been recommended,” top government sources told IANS. Clinical trials of Bharat Biotech’s ‘BBV154’ — a novel adenovirus vectored, and intranasal vaccine for coronavirus — will be conducted at various locations. The vaccine will be single-dosed.

According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19.

The vaccine has demonstrated protective efficacy in mice and hamsters. Mice and hamsters immunized with its single-dose conferred superior protection against the SARS-CoV-2 challenge, “more so than one or two intramuscular immunizations of the same vaccine and dose.”

“Thus, intranasal immunization of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission,” Bharat Biotech said in a statement.

On January 3, two intramuscular vaccines – Bharat Biotech’s Covaxin and Oxford-AstraZeneca’s Covishield manufactured by the Serum Institute of India were approved for restricted emergency use and have been administered to over four lakh people till now. Both are two-dose vaccines.

While the full efficacy of Covaxin is yet to be determined, it was given the go-ahead by the DCGI citing ‘public interest’. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).

Public health experts believe that intranasal vaccines for coronavirus, administered through the nose rather than muscles, can be a potential game-changer in India’s fight against the coronavirus pandemic.

Last month, Pune-based Serum Institute of India and Codagenix Inc had announced that they have received regulatory approval in the United Kingdom to begin an early-stage trial of their single-dose, intranasal coronavirus vaccine.

(Aakanksha Khajuria can be contacted at [email protected])

Continue Reading

Blog

Covid-19 vax: WHO warns of ‘catastrophic moral failure’

He said over 39 million vaccine doses had been given in 49 richer states – but one poor nation had only 25 doses.

Published

on

Tedros Adhanom Ghebreyesus WHO

Geneva, Jan 19 : The world faces a “catastrophic moral failure” because of unequal Covid-19 vaccine policies, the head of the World Health Organization (WHO) has warned.

WHO chief Tedros Adhanom Ghebreyesus said it was not fair for younger, healthy people in richer nations to get injections before vulnerable people in poorer states, the BBC reported.

He said over 39 million vaccine doses had been given in 49 richer states – but one poor nation had only 25 doses.

Meanwhile, both the WHO and China were criticised for their Covid response.

An independent panel commissioned by the WHO said the UN public health body should have declared an international emergency earlier, and also rapped China for not taking public health measures sooner.

So far, China, India, Russia, the UK and the US have all developed Covid vaccines, with others being made by multinational teams – like the American-German Pfizer vaccine.

Almost all of these nations have prioritised distribution to their own populations.

Speaking at a WHO executive board session on Monday, Tedros said: “I need to be blunt: the world is on the brink of a catastrophic moral failure – and the price of this failure will be paid with lives and livelihoods in the world’s poorest countries.”

Tedros said a “me-first” approach would be self-defeating because it would push up prices and encourage hoarding.

“Ultimately, these actions will only prolong the pandemic, the restrictions needed to contain it, and human and economic suffering,” he added.

The WHO head called for a full commitment to the global vaccine-sharing scheme Covax, which is due to start rolling out next month.

“My challenge to all member states is to ensure that by the time World Health Day arrives on April 7, Covid-19 vaccines are being administered in every country, as a symbol of hope for overcoming both the pandemic and the inequalities that lie at the root of so many global health challenges,” Tedros said.

So far, more than 180 countries have signed up to the Covax initiative, which is supported by the WHO and a group of international vaccine advocacy groups. Its aim is to unite countries into one bloc so they have more power to negotiate with drug companies.

Ninety-two countries – all of them low or middle-income – will have their vaccines paid for by a fund sponsored by donors.

“We have secured two billion doses from five producers, with options of more than one billion more doses, and we aim to start deliveries in February,” Tedros said.

Continue Reading

Cities

Karnataka’s Covid vaccine recipient dies of heart stroke: Minister

The vaccination was launched in the southern state on January 16 with fanfare after Prime Minister Narendra Modi inaugurated the drive across the country from New Delhi through video-conferencing.

Published

on

By

COVAXIN Corona Covid vaccine

Bengaluru: A recipient of Covid vaccine in Karnataka’s Ballari city died of heart stroke (myocardial infarction) and not due to the vaccine, said state Health Minister K. Sudhakar on Monday.

“The death of the 43-year-old vaccine beneficiary at Ballari was not due to vaccine but from heart stroke or myocardial infarction. He took the jab on Saturday (January 16) but had no side-effects since then. He was diabetic and had hypertension,” clarified Sudhakar in a statement in Kannada here.

Ballari is about 310km northwest of Bengaluru in the southern state.

The victim was a resident of Kamalapura and was working as a group-D worker in the state-run Sandur general hospital.

“Though doctors at the state-run Vijayanagar Institute of Medical Sciences tried to revive the victim’s heart and gave emergency healthcare, he did not respond to the treatment. His autopsy report is awaited,” said Sudhakar, a medical doctor by profession.

“Though the victim worked for two days after taking the shot, he was admitted to the hospital after he complained of chest pain earlier in the day,” a health department official said.

According to a statement by the health department, the cause of the worker’s death is due to anterior wall infarction with cardio-pulmonary failure.

ECG and ECHO reports also concluded that it was a death due to myocardial infarction.

“The AEFI (Adverse Event Following Immunisation) committee met following the worker’s death and took his history. After looking at his ECG and ECHO reports, they concluded that it was a death due to myocardial infarction,” said Ballari district health officer H.L.Janardhan.

The vaccination was launched in the southern state on January 16 with fanfare after Prime Minister Narendra Modi inaugurated the drive across the country from New Delhi through video-conferencing.

The state health department has decided to use Covishield in 24 of the 31 districts across the state and Covaxin in 6 districts, including Ballari under the emergency use situation.

Continue Reading
Advertisement

Most Popular